New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 13, 2014
18:55 EDTAMGN, CSCO, CNAT, KND, NDLS, AZPNOn The Fly: After Hours Movers
UP AFTER EARNINGS: Aspen Technology (AZPN), up almost 3% after reporting better than expected Q4 results and giving Q1 and FY15 guidance on its earnings conference call. ALSO HIGHER: Kindred Healthcare (KND), up more than 1% after Point72 reported a 5.1% passive stake in the company. DOWN AFTER EARNINGS: Cisco Systems (CSCO), down 1.2% after reporting Q4 results, giving Q1 guidance, and announcing that it is cutting 8% of its workforce... Noodles & Company (NDLS), down 21.2% after reporting Q2 results and "tempering" its FY14 outlook... Conatus Pharmaceuticals (CNAT), down 13.6% after reporting Q2 results and announcing it is deferring the results of its NAFLD/NASH clinical trial to 1Q15. ALSO LOWER: Amgen (AMGN), down 2.15% after announcing the Phase 3 Kyprolis FOCUS clinical trial did not meet its primary endpoint.
News For AZPN;KND;CSCO;NDLS;CNAT;AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 7, 2015
10:19 EDTCSCOFrontier Communications appoints Kathleen Weslock EVP, Chief People Officer
Subscribe for More Information
09:50 EDTCSCOCisco to acquire MaintenanceNet for $139M in cash
Subscribe for More Information
09:33 EDTCSCOActive equity options trading on open
Subscribe for More Information
July 6, 2015
09:35 EDTCSCOActive equity options trading on open
Subscribe for More Information
July 2, 2015
13:36 EDTCSCOOn The Fly: Technical notes on earnings season calendar effects
The doldrums have persisted without a great deal of index volatility heading into Q2 earnings season. Until we are into the bulk of the season, we aren't likely to have sufficient catalysts to move far, barring an exogenous event. What traders need to be aware of is how compressed this earnings season really is. The increased flow of earnings news within a shorter span could lead to some bigger moves. How short? The old school way of determining the bounds of earnings season starts with Alcoa (AA) and ends with Cisco (CSCO). This time around, Alcoa is on July 8 and Cisco is on August 12, putting the season at just over a month in calendar time. Contrast this with Q4 earnings season, which can take nearly seven weeks in some cases. Another factor to be aware of: in the first week of earnings this season, there are just a relative handful of S&P 500 names reporting. By the time Cisco reports, the bulk will be done. We really are looking at more like a three week window. If the direction of earnings surprises are consistent, the market might see its first real push up or down that breaks the tight range with solid momentum. If not, market watchers are likely to see a spate of volatility in a market that has become used to flatter conditions, where volatility has been better for a sale. Choppy earnings could make that strategy more problematic. Planning out ahead is critically important too, as the day of the week can matter. Wednesdays and Thursdays tend to be the peak days for reports, making them more subject to market gyrations. Friday afternoons tend to be a day in which companies with genuinely bad news try to sneak it out. Use the forthcoming holiday wisely; we may be in for a bumpier ride ahead.
July 1, 2015
10:07 EDTCSCOGoogle, Apple seen benefiting from Internet of Things emergence
Subscribe for More Information
June 30, 2015
11:36 EDTAMGNRumor: Amgen moves up on speculation of an investor stake
Subscribe for More Information
10:42 EDTCSCOCisco strengthens security story with OpenDNS buy, says Wells Fargo
Subscribe for More Information
08:04 EDTCSCOCisco to acquire OpenDNS for $635M
Subscribe for More Information
07:13 EDTCSCONasdaq to hold a conference
Subscribe for More Information
07:03 EDTAMGNCelgene leaps forward in immuno-oncology with Juno deal, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said that Celgene (CELG) effectively spent $1B to buy into adoptive T cell therapy and own all of Juno Therapeutics' (JUNO) opportunities outside the U.S., leaping the company into a leading position in the immuno-oncology space. Schimmer additionally thinks Celgene's transaction should help boost investor confidence about the utility and value of CAR and TCR therapies, noting that he sees Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), bluebird bio (BLUE) and the Amgen (AMGN)-Kite Pharma (KITE) partnership as best positioned to compete in this rapidly advancing field. The analyst keeps an Overweight rating and $144 price target on Celgene.
06:11 EDTCSCOCisco, Schneider Electric partner to build resilient control system networks
Subscribe for More Information
June 29, 2015
09:35 EDTCSCOActive equity options trading on open
Subscribe for More Information
June 25, 2015
16:06 EDTNDLSNoodles & Company appoints Mark Mears as CMO
Subscribe for More Information
16:04 EDTNDLSNoodles & Company appoints Mark Mears as CMO
Subscribe for More Information
07:23 EDTCSCOHouse Energy & Commerce Committee to hold a hearing
Subscribe for More Information
07:09 EDTCNATConatus announces initial baseline data from Phase 2b POLT-HCV-SVR trial
Conatus announced pre-treatment biomarker and histology data from the first 16 patients enrolled in the company's Phase 2b clinical trial of its lead drug candidate, emricasan, in post-orthotopic liver transplant, or POLT, recipients. These patients have reestablished liver fibrosis or cirrhosis post-transplant as a result of recurrent hepatitis C virus, or HCV, infection and have successfully achieved a sustained viral response, or SVR, following HCV antiviral therapy, or POLT-HCV-SVR. Among the first 16 patients enrolled, more than 85% achieved SVRs using recently approved oral HCV antiviral treatments. The excitement generated by these new treatments altered enrollment patterns during the early stage of the POLT-HCV-SVR trial, and their rapid market penetration is now expanding the trial-eligible population. The double-blind, placebo-controlled trial was initiated in May 2014 in patients with Ishak Fibrosis Scores of 2 to 4. Consistent with the company's initial registration focus on the development of a treatment for cirrhosis, the trial was expanded in early 2015 to include patients with Ishak 5 and is currently expanding to Ishak 6. Patients are being randomized 2:1 to receive either 25 mg of emricasan or placebo orally twice daily for 24 months and will be followed for another month post-treatment. The primary endpoint in this exploratory proof-of-concept trial is the change in the Ishak Fibrosis Score compared with placebo. The trial will also evaluate histological markers of inflammation, key serum biomarkers, and the safety and tolerability of emricasan in the target patient population. Enrollment of approximately 60 total planned patients is on track for release of final top-line results in the first half of 2018.
June 24, 2015
08:31 EDTCSCOInvestors should weigh waiting for better Arista entry point, says Pacific Crest
Pacific Crest says that Arista's (ANET) new Cloudvision software should have only a minor impact on its 2H15 results. The firm recommends that investors consider waiting for a lower entry point before buying the stock. The firm thinks that such an entry point could materialize during the company's trial versus Cisco (CSCO) this summer. It keeps an $88 price target and Overweight rating on Arista..
07:56 EDTAMGNAmgen management to meet with Evercore ISI
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use